Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 13, 2022 3:59pm

152 Views

Post# 35169391

RE:RE:RE:RE:RE:RE:Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

An full acquisition of an independent company does not include commercial milestones. All of the deal value is cash up-front.

Nimbus Lakshimi was a subsidiary of Nimbus Therapeutics and therefore commercial milestones could be part of the deal.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"